IN2006MU00429A - - Google Patents

Info

Publication number
IN2006MU00429A
IN2006MU00429A IN429MU2006A IN2006MU00429A IN 2006MU00429 A IN2006MU00429 A IN 2006MU00429A IN 429MU2006 A IN429MU2006 A IN 429MU2006A IN 2006MU00429 A IN2006MU00429 A IN 2006MU00429A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Shlomit Wizel
Marina Yu Etinger
Michael Yuzefovich
Ben-Zion Dolitzky
Valerie Niddam-Hildesheim
Judith Aronhime
Boris Pertsikov
Gennady A Nisnevich
Boris Tishin
Dina Blasberger
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2006MU00429A publication Critical patent/IN2006MU00429A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
IN429MU2006 2001-09-07 2006-04-13 IN2006MU00429A (cs)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31785001P 2001-09-07 2001-09-07
US34227301P 2001-12-21 2001-12-21
US38650502P 2002-06-05 2002-06-05
US40383802P 2002-08-14 2002-08-14

Publications (1)

Publication Number Publication Date
IN2006MU00429A true IN2006MU00429A (cs) 2007-08-17

Family

ID=27502150

Family Applications (2)

Application Number Title Priority Date Filing Date
IN133MU2004 IN2004MU00133A (cs) 2001-09-07 2004-02-20
IN429MU2006 IN2006MU00429A (cs) 2001-09-07 2006-04-13

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN133MU2004 IN2004MU00133A (cs) 2001-09-07 2004-02-20

Country Status (16)

Country Link
US (2) US6849736B2 (cs)
EP (1) EP1436295A4 (cs)
JP (2) JP5043286B2 (cs)
KR (1) KR100774271B1 (cs)
CN (1) CN1551880A (cs)
CA (1) CA2457835A1 (cs)
CZ (1) CZ2004446A3 (cs)
HR (1) HRP20040321A2 (cs)
HU (1) HUP0500753A3 (cs)
IL (1) IL160721A0 (cs)
IN (2) IN2004MU00133A (cs)
MX (1) MXPA04002192A (cs)
NO (1) NO20041449L (cs)
PL (1) PL374179A1 (cs)
SK (1) SK1592004A3 (cs)
WO (1) WO2003022209A2 (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
JP2005508993A (ja) * 2001-11-14 2005-04-07 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビルの合成及び精製
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
ATE335743T1 (de) * 2002-10-16 2006-09-15 Teva Pharma Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
ATE301455T1 (de) * 2003-12-09 2005-08-15 Helm Ag Pharmazeutische zubereitung enthaltend valaciclovir
CN1976933A (zh) * 2004-06-30 2007-06-06 特瓦制药工业有限公司 减少晶体盐酸伐昔洛韦中的残留醇的方法
WO2006035452A1 (en) * 2004-09-27 2006-04-06 Matrix Laboratories Ltd Novel pseudomorph of valaciclovir hydrochloride
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US7872075B2 (en) * 2005-10-07 2011-01-18 Exxonmobil Chemical Patents Inc. Peroxide-cured thermoplastic vulcanizates and process for making the same
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
GB201222287D0 (en) * 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
KR20200022712A (ko) * 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
US5856481A (en) * 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ZA97400B (en) * 1996-01-19 1997-11-13 Glaxo Group Ltd Valaciclovir.
US6040446A (en) * 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
JP2005508993A (ja) * 2001-11-14 2005-04-07 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビルの合成及び精製
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Also Published As

Publication number Publication date
MXPA04002192A (es) 2005-02-17
WO2003022209A9 (en) 2004-04-08
US20050187229A1 (en) 2005-08-25
EP1436295A4 (en) 2007-07-11
PL374179A1 (en) 2005-10-03
JP2005526694A (ja) 2005-09-08
CZ2004446A3 (cs) 2005-01-12
KR100774271B1 (ko) 2007-11-08
US20030114470A1 (en) 2003-06-19
JP5043286B2 (ja) 2012-10-10
CA2457835A1 (en) 2003-03-20
CN1551880A (zh) 2004-12-01
KR20040036932A (ko) 2004-05-03
US6849736B2 (en) 2005-02-01
HUP0500753A2 (hu) 2005-11-28
SK1592004A3 (sk) 2005-03-04
WO2003022209A2 (en) 2003-03-20
IL160721A0 (en) 2004-08-31
EP1436295A2 (en) 2004-07-14
HUP0500753A3 (en) 2006-05-29
WO2003022209A3 (en) 2003-11-27
HRP20040321A2 (en) 2004-08-31
IN2004MU00133A (cs) 2005-04-29
JP2012162565A (ja) 2012-08-30
NO20041449L (no) 2004-04-06

Similar Documents

Publication Publication Date Title
BE2022C531I2 (cs)
BE2022C502I2 (cs)
BE2022C547I2 (cs)
BE2017C057I2 (cs)
BE2015C046I2 (cs)
BE2014C004I2 (cs)
BE2017C050I2 (cs)
BE2011C034I2 (cs)
BE2007C047I2 (cs)
AU2002307149A8 (cs)
JP2002098116A5 (cs)
BRPI0209186B1 (cs)
JP2002169712A5 (cs)
IN2006MU00429A (cs)
BE2016C021I2 (cs)
CH1379220H1 (cs)
BRPI0204884B1 (cs)
BE2017C059I2 (cs)
HU0201842D0 (cs)
JP2002230202A5 (cs)
JP2002229403A5 (cs)
JP2001339492A5 (cs)
JP2001338431A5 (cs)
JP2002173041A5 (cs)
JP2002014934A5 (cs)